Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Pharmacokinetics of Ferric bepectate - a new intravenous iron drug for treating iron deficiency

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Oral Immunosuppressive Treatment of Myasthenia Gravis in Denmark: A Nationwide Drug Utilization Study, 1996-2013

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Novel Treatment Options

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early physical and psycho-educational rehabilitation in patients with coronary artery bypass grafting: A randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Obesity-induced CYP2E1 activity in children

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Potential pharmacobezoar formation of large size extended-release tablets and their dissolution - an in vitro study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Sparsom evidens for effekt og sikkerhed af propranolol ved eksamensangst

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ventrikelaspiration er meget sjældent indiceret ved forgiftninger

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

IV iron is indicated in clinical conditions, where rapid anaemia alleviation and repletion of iron stores are required. The acute toxicity of IV iron is ascribed to the presence of labile iron in plasma. Thus, shorter plasma residence time might improve the safety profile, even for compounds holding-on the iron tightly. In this single-centre, open-label, single-dose escalation study, we evaluated the elimination kinetics of ferric bepectate (FBP) compared to those of ferric carboxymaltose (FCM). Thirty-three iron-depleted anaemic patients who had undergone cardiac surgery were included and received 200, 500 or 1500 mg FBP or 500 mg FCM. Plasma drug curves were subjected to model-free analysis. Because saturation kinetics was found, a compartmental model with limited elimination capacity was applied. Urinary iron excretion was also analysed. The initial non-compartmental analysis revealed an increasing AUC/dose ratio for FBP. For both drugs, the central distribution compartment corresponded to plasma volume, and elimination followed Michaelis-Menten saturation kinetics. Maximal elimination rates (Vmax) were 224 mg/hr and 81 mg/hr for FBP 500 mg and FCM 500 mg, respectively; drug concentrations at half Vmax (Km), 99 mg/L and 212 mg/L, respectively; and terminal plasma half-life (T½), 3.05 hr and 8.96 hr, respectively. Both drugs were equally effective in eliciting an early ferritin rise. Urinary iron excretion was measurable in all patients receiving FCM but not in those receiving FBP, which was well tolerated. Intravenous iron drugs are subject to capacity-limited elimination with different saturation thresholds. Urinary iron excretion can be used as a surrogate for labile plasma iron. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalBasic & clinical pharmacology & toxicology
ISSN1742-7843
DOIs
Publication statusE-pub ahead of print - 6 Mar 2019

ID: 56798991